Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Oncology and Oncohematology, University of Milan, Milan, Italy.
Orphanet J Rare Dis. 2021 Oct 9;16(1):415. doi: 10.1186/s13023-021-02036-4.
Congenital hemolytic anemias (CHAs) comprise defects of the erythrocyte membrane proteins and of red blood cell enzymes metabolism, along with alterations of erythropoiesis. These rare and heterogeneous conditions may generate several difficulties from the diagnostic point of view. Membrane defects include hereditary spherocytosis and elliptocytosis, and the group of hereditary stomatocytosis; glucose-6-phosphate dehydrogenase and pyruvate kinase, are the most common enzyme deficiencies. Among ultra-rare forms, it is worth reminding other enzyme defects (glucosephosphate isomerase, phosphofructokinase, adenylate kinase, triosephosphate isomerase, phosphoglycerate kinase, hexokinase, and pyrimidine 5'-nucleotidase), and congenital dyserythropoietic anemias. Family history, clinical findings (anemia, hemolysis, splenomegaly, gallstones, and iron overload), red cells morphology, and biochemical tests are well recognized diagnostic tools. Molecular findings are increasingly used, particularly in recessive and de novo cases, and may be fundamental in unraveling the diagnosis. Notably, several confounders may further challenge the diagnostic workup, including concomitant blood loss, nutrients deficiency, alterations of hemolytic markers due to other causes (alloimmunization, infectious agents, rare metabolic disorders), coexistence of other hemolytic disorders (autoimmune hemolytic anemia, paroxysmal nocturnal hemoglobinuria, etc.). Additional factors to be considered are the possible association with bone marrow, renal or hepatic diseases, other causes of iron overload (hereditary hemochromatosis, hemoglobinopathies, metabolic diseases), and the presence of extra-hematological signs/symptoms. In this review we provide some instructive clinical vignettes that highlight the difficulties and confounders encountered in the diagnosis and clinical management of CHAs.
先天性溶血性贫血(CHAs)包括红细胞膜蛋白缺陷和红细胞酶代谢异常,以及红细胞生成改变。这些罕见且异质性的疾病可能会在诊断方面造成多种困难。膜缺陷包括遗传性球形细胞增多症和椭圆形细胞增多症,以及遗传性口形细胞增多症组;葡萄糖-6-磷酸脱氢酶和丙酮酸激酶是最常见的酶缺乏症。在超罕见形式中,值得提醒的是其他酶缺陷(葡萄糖磷酸异构酶、磷酸果糖激酶、腺苷酸激酶、磷酸三糖异构酶、磷酸甘油酸激酶、己糖激酶和嘧啶 5'-核苷酸酶)和先天性红细胞生成异常性贫血。家族史、临床发现(贫血、溶血、脾肿大、胆石症和铁过载)、红细胞形态和生化检查是公认的诊断工具。分子发现越来越多地被使用,特别是在隐性和新生病例中,并且可能对阐明诊断至关重要。值得注意的是,几种混杂因素可能会进一步挑战诊断工作,包括伴随的失血、营养缺乏、由于其他原因(同种免疫、感染因子、罕见代谢紊乱)导致的溶血标志物改变、其他溶血性疾病的共存(自身免疫性溶血性贫血、阵发性夜间血红蛋白尿等)。需要考虑的其他因素包括与骨髓、肾脏或肝脏疾病的可能关联、铁过载的其他原因(遗传性血色素沉着症、血红蛋白病、代谢疾病)以及存在血液系统以外的体征/症状。在这篇综述中,我们提供了一些有益的临床病例,突出了 CHAs 的诊断和临床管理中遇到的困难和混杂因素。